{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:20:34Z","timestamp":1784042434308,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["G-2018PG-CD009"],"award-info":[{"award-number":["G-2018PG-CD009"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Different antibiotic classes were reported to have variable effects on immunogenicity towards anti-tumour necrosis factor [TNF] agents. However, the impact of antibiotic administration on biologic treatment durability was not investigated. We aimed to assess the association between antibiotic treatment and persistence of different classes of biologic therapy in inflammatory bowel disease [IBD] patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the epi-IIRN, a nationwide registry of all Israeli IBD patients were analysed. All patients who filled a prescription of either infliximab, adalimumab, vedolizumab, or ustekinumab, were included. Treatment cessation was defined as drug discontinuation of at least 6 months. Macrolides, cephalosporins, fluoroquinolones, and penicillins with beta-lactamase inhibitors were selected as primary exposure variables. Survival analysis was performed using marginal structural models for each drug separately.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In all 13 513 IBD patients, with a total of 39 600 patient-years, were included. Significant differences of overall treatment persistence were demonstrated, with highest persistence rates for ustekinumab and the lowest for infliximab treatment. Macrolides were found to be significantly associated with reduced risk of infliximab cessation (adjusted hazard ratio [aHR] 0.72, 95% CI 0.62-0.89]. Fluoroquinolones and cephalosporins were associated with an elevated risk of adalimumab treatment cessation [aHR 1.33, 95% CI 1.22-1.46; and aHR 1.20, 95% CI 1.08-1.34, respectively]. No significant effects of the studied antibiotics were observed in ustekinumab and vedolizumab users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Specific antibiotic classes are associated with duration of anti-TNF treatment, but not with durability of vedolizumab or ustekinumab treatments. Further research is required to study the effect of specific antibiotics on response to biologics.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad070","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T13:39:11Z","timestamp":1682084351000},"page":"1410-1417","source":"Crossref","is-referenced-by-count":4,"title":["Association of Antibiotic Use with Durability of Biologic Agents in Inflammatory Bowel Disease: a Report from the epi-IIRN"],"prefix":"10.1093","volume":"17","author":[{"given":"Yuri","family":"Gorelik","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Rambam Health Care Campus , Haifa , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Ghersin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rambam Health Care Campus , Haifa , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deema","family":"Shlon","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rambam Health Care Campus , Haifa , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chagit","family":"Friss","sequence":"additional","affiliation":[{"name":"Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, Hebrew University of Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Lujan","sequence":"additional","affiliation":[{"name":"Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, Hebrew University of Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiska","family":"Loewenberg Weisband","sequence":"additional","affiliation":[{"name":"Clalit Health Services, Clalit Research Institute , Tel-Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Greenfeld","sequence":"additional","affiliation":[{"name":"Maccabi Health Services , Tel-Aviv , Israel"},{"name":"The Sackler Faculty of Medicine , Tel Aviv University , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revital","family":"Kariv","sequence":"additional","affiliation":[{"name":"Maccabi Health Services , Tel-Aviv , Israel"},{"name":"The Sackler Faculty of Medicine , Tel Aviv University , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natan","family":"Ledderman","sequence":"additional","affiliation":[{"name":"Meuhedet Health Services , Meuhedet Research Institue, Tel-Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Matz","sequence":"additional","affiliation":[{"name":"Leumit Health Services , Leumit Research Institue, Tel-Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rabin Medical Center , Petah Tikva , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haggai","family":"Bar-Yoseph","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rambam Health Care Campus , Haifa , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Chowers","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rambam Health Care Campus , Haifa , Israel"},{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology , Haifa , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Turner","sequence":"additional","affiliation":[{"name":"Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, Shaare Zedek Medical Center, Hebrew University of Jerusalem , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2023102016290920000_CIT0001","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"key":"2023102016290920000_CIT0002","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2023102016290920000_CIT0003","article-title":"Tailoring anti-TNF therapy in IBD: Drug levels and disease activity","volume":"243","author":"Ben-Horin","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023102016290920000_CIT0004","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"2023102016290920000_CIT0005","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"67","author":"Honap","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2023102016290920000_CIT0006","article-title":"Review article: Loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"987","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2023102016290920000_CIT0007","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn\u2019s disease or ulcerative colitis: a systematic review and meta-analysis","author":"Peyrin-Biroulet","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023102016290920000_CIT0008","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ibd\/izy171","article-title":"Predictors and management of loss of response to vedolizumab in inflammatory bowel disease","volume":"24","author":"Shmidt","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2023102016290920000_CIT0009","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/apt.14016","article-title":"Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort","volume":"45","author":"Ma","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2023102016290920000_CIT0010","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2019.08.009","article-title":"Infliximab-tumor necrosis factor complexes elicit formation of anti-drug antibodies","volume":"157","author":"Bar-Yoseph","year":"2019","journal-title":"Gastroenterology"},{"key":"2023102016290920000_CIT0011","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023102016290920000_CIT0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023102016290920000_CIT0013","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","article-title":"The microbiome in inflammatory bowel disease: Current status and the future ahead","volume":"146","author":"Kostic","year":"2014","journal-title":"Gastroenterology"},{"key":"2023102016290920000_CIT0014","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/mSystems.00188-17","article-title":"Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction","volume":"3","author":"Zhou","year":"2018","journal-title":"MSystems"},{"key":"2023102016290920000_CIT0015","article-title":"Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNF\u03b1 therapy in inflammatory bowel disease patients: a report from the epi-IIRN","author":"Gorelik","year":"2021.","journal-title":"Gut"},{"key":"2023102016290920000_CIT0016","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2147\/CLEP.S151339","article-title":"Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study","volume":"10","author":"Friedman","year":"2018","journal-title":"Clin Epidemiol"},{"key":"2023102016290920000_CIT0017","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/j.cgh.2021.04.007","article-title":"Perianal Crohn\u2019s disease is associated with poor disease outcome: a nationwide study from the epiIIRN Cohort","volume":"20","author":"Atia","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023102016290920000_CIT0018","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"2023102016290920000_CIT0019","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2023102016290920000_CIT0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"2023102016290920000_CIT0021","article-title":"Features of fecal and colon microbiomes associate with responses to biologic therapies for inflammatory bowel diseases: a systematic review","volume":"1054","author":"Estevinho","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023102016290920000_CIT0022","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chom.2021.06.019","article-title":"Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease","volume":"29","author":"Lee","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2023102016290920000_CIT0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell Host Microbe"},{"key":"2023102016290920000_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00531-6","article-title":"A single early-in-life macrolide course has lasting effects on murine microbial network topology and immunity","volume":"8","author":"Ruiz","year":"2017","journal-title":"Nat Commun"},{"key":"2023102016290920000_CIT0025","article-title":"Long-term use of ceftriaxone sodium induced changes in gut microbiota and immune system","volume":"7","author":"Guo","year":"2017","journal-title":"Sci Rep"},{"key":"2023102016290920000_CIT0026","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023102016290920000_CIT0027","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/MIB.0000000000001072","article-title":"Treatment persistence for infliximab versus adalimumab in Crohn\u2019s disease: A 14-year single-center experience","volume":"23","author":"Olivera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2023102016290920000_CIT0028","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ibd\/izy322","article-title":"Treatment persistence of infliximab versus adalimumab in ulcerative colitis: a 16-year single-center experience","volume":"25","author":"Pouillon","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2023102016290920000_CIT0029","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort [PANIC] study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2023102016290920000_CIT0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/apt.16478","article-title":"Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study","volume":"54","author":"Blesl","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2023102016290920000_CIT0031","doi-asserted-by":"crossref","article-title":"Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study","author":"Blesl","DOI":"10.1080\/00365521.2022.2088248"},{"key":"2023102016290920000_CIT0032","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/EDE.0b013e31818f69ce","article-title":"Marginal structural models for the estimation of direct and indirect effects","volume":"20","author":"Vanderweele","year":"2009","journal-title":"Epidemiology"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad070\/50415174\/jjad070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/9\/1410\/52307724\/jjad070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/9\/1410\/52307724\/jjad070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T23:43:14Z","timestamp":1729294994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/9\/1410\/7135636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,10,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad070","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,4,21]]}}}